ADC Therapeutics (ADCT) Q2 2026 earnings summary

Executive summary

• Net product revenues for Q2 2026 were $18.6 million, up from $18.1 million in Q2 2025, driven by price increases and stable commercial execution for ZYNLONTA in 3L+ DLBCL.

• Strategic reorganization in June 2026 reduced workforce by 17%, expected to save $10 million annually and support key clinical, regulatory, and manufacturing activities.

• Cash and cash equivalents stood at $219.1 million as of June 30, 2026, providing a runway at least into 2028.

• Net loss narrowed significantly to $16.6 million for Q2 2026, reflecting lower R&D and restructuring costs.

• Company is evaluating regulatory paths for ZYNLONTA following FDA concerns on LOTIS-5 trial data.

Financial highlights

• Total revenue for Q2 2026 was $19.2 million, a 2.2% increase year-over-year, with product revenues at $18.6 million.

• Cost of product sales rose to $2.3 million from $0.8 million year-over-year, mainly due to increased personnel and manufacturing costs.

• Adjusted operating expenses for Q2 2026 were $37.2 million, down 22% year-over-year due to lower R&D expenses.

• Net loss per share improved to $0.11 from $0.50; adjusted net loss per share was $0.11, down from $0.25.

• Operating cash outflow was $41.5 million for the six months, a significant improvement from $80.4 million in the prior year.

Outlook and guidance

• Cash runway is expected to extend at least into 2028, supporting strategic objectives and minimum liquidity requirements.

• Anticipates ZYNLONTA revenue growth beginning in 2027, with expansion into earlier lines of therapy and new indications.

• Preparing for regulatory submissions and potential Breakthrough Therapy designation for LOTIS-7 and MZL.

• R&D expenses projected to decrease further in 2026 due to completed restructuring and program prioritization.

• Updated FL data presentation expected in Q2 2027.